Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of EI1071 in Healthy Volunteers
NCT04238364Phase 1Completed
- Sponsor
- Elixiron Immunotherapeutics
- Start
- Dec 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing EI-1071 Tablet with Placebo (2 arms). Primary endpoints: Number of subjects with treatment-emergent adverse events after single ascending doses at 7 days, Number of subjects with treatment-emergent adverse events after multiple ascending doses at 21 days and 1 more. Started Dec 2019; status: completed.
02
Drugs
enrupatinib
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04238364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04238364.